Here are five top-read Becker's headlines on orthobiologics and regenerative medicine in 2022:
Spine surgeon steps down as CEO of biologics company: Kingsley Chin, MD, is stepping down as CEO of NanoFuse Biologics following the company's merger into a newly formed medtech company.
$450M acquisition to shake up the orthopedic device industry: Bioventus has exercised its call option to acquire Israeli devicemaker CartiHeal for up to $450 million following the FDA's premarket approval of the Agili-C implant on March 29.
Orthopedic surgeon awarded $1.3M for stem cell research: The California Institute of Regenerative Medicine has provided a $1.3 million grant to Kevin Stone, MD, chair of the Stone Research Foundation, and Mani Vessal, PhD, senior director of research and operation for the foundation, to advance a paste graft technique for cartilage repair.
Former Stryker president joins board of regenerative medicine company: Timothy Scannell, former president and COO at Stryker, was added to the board of directors at Collagen Matrix.
Regenerative medicine in 10 years: 5 surgeon predictions: Regenerative medicine in spine and orthopedics is gaining momentum, and many surgeons expect further development and research for the field in the near future. Five spine and orthopedic surgeons share their predictions.